DENTSPLY SIRONA (XRAY)
NASDAQ:XRAY
Want to see XRAY full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.36Last Year’s EPS
0.52Same Quarter Last Year
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced mix of encouraging operational and financial actions alongside notable near-term challenges. Positives include improved operating cash flow, active deleveraging (≈$79–$80M debt retired), early cost savings (≈$20M OpEx reduction in Q1) and meaningful innovation launches (AI diagnostic aid with ~46% sensitivity improvement, dental MRI clearance, new endodontic tools). Management also maintained full-year guidance and highlighted distributor expansion and early commercial traction. Offsetting these are material constant-currency revenue declines (Q1 cc sales down 6.7%, down 4.5% excluding one-time items), significant margin compression (adjusted EBITDA down 430 bps; gross profit down 560 bps), softness in several key segments (OIS, EDS, IPS, CTS), tariff-related margin pressure, distributor destocking, and an expected ~$30M inventory sell-through headwind later in the year. Given the roughly balanced set of meaningful positives (cash, cost saves, innovation, distribution) and negatives (sales declines, margin pressure, macro/timing risks), the overall tone is cautiously constructive but realistic about near-term headwinds.Company Guidance
Revenue and Guidance Maintained
Q1 revenue of $880 million (as-reported +0.1% vs. prior year quarter). Company maintained full-year 2026 guidance of net sales $3.5B–$3.6B and adjusted EPS $1.40–$1.50, indicating management confidence in the return-to-growth plan.
Improved Operating Cash Flow and Deleveraging
Operating cash flow improved to $40 million in Q1 vs. $7 million a year ago. Cash and cash equivalents finished at $190 million, net debt to EBITDA was 3.3x, and the company retired approximately $79–$80 million of debt during the quarter, prioritizing debt reduction.
Early Cost Savings from Restructuring
Return-to-growth restructuring remains on track for $120 million of annual savings; early proof points include an approximate $20 million reduction in operating expenses in Q1 and a constant-currency OpEx decline of $20 million.
Innovation and Product Launches
Started commercial rollout of multiple new products: SmartView Detect (AI-enabled diagnostic aid) which increased detection sensitivity by ~46% in clinical evaluation; FDA clearance of dental-dedicated MRI; Reciproc Minima file system and X-Smart Go cordless endomotor; Sureti launches (female adoption expanding, male version launched). R&D spend increased year over year to support innovation.
Selective Segment & Regional Strengths
Wellspect Healthcare grew +3.4% on a constant currency basis (EMEA +4%). SureSmile saw +11% growth in EMEA. Company cited double-digit growth in parts of APAC and EDS (regionally) as quarter highlights and noted bright spots such as increased demand for mills in the U.S.
Expanded Distribution and Commercial Traction
Signed multiple distributor agreements (four new distributor agreements year-to-date), including an expanded agreement with Atlanta Dental Supply (connected tech portfolio added Aug 1). Early traction included Benco installing its first CEREC system under a new agreement ahead of schedule.
XRAY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XRAY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $11.37 | $11.14 | -2.02% |
Feb 26, 2026 | $12.71 | $14.68 | +15.50% |
Nov 06, 2025 | $12.44 | $10.86 | -12.68% |
Aug 07, 2025 | $13.31 | $12.87 | -3.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does DENTSPLY SIRONA (XRAY) report earnings?
DENTSPLY SIRONA (XRAY) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is DENTSPLY SIRONA (XRAY) earnings time?
DENTSPLY SIRONA (XRAY) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XRAY EPS forecast?
XRAY EPS forecast for the fiscal quarter 2026 (Q2) is 0.36.